Who 2016 Definition of Chronic Myeloid Leukemia and Tyrosine Kinase Inhibitors
Who 2016 Definition of Chronic Myeloid Leukemia and Tyrosine Kinase Inhibitors
About this item
Full title
Author / Creator
Publisher
Turkey: Türk Hematoloji Derneği
Journal title
Language
English
Formats
Publication information
Publisher
Turkey: Türk Hematoloji Derneği
Subjects
More information
Scope and Contents
Contents
Philadelphia (Ph*)/BCR-ABL1-positive chronic myeloid leukemia (CML) is considered as a chronic life-long disease, which could be manageable with tyrosine kinase inhibitor (TKI) drugs. The aim of TKI drug treatment is to provide age- and sex-matched duration of life in a given patient with CML. Personalized CML treatment with TKI drugs is the key st...
Alternative Titles
Full title
Who 2016 Definition of Chronic Myeloid Leukemia and Tyrosine Kinase Inhibitors
Authors, Artists and Contributors
Author / Creator
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_doaj_primary_oai_doaj_org_article_d401534f053c4293b22bc2a0cd0405f3
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_doaj_primary_oai_doaj_org_article_d401534f053c4293b22bc2a0cd0405f3
Other Identifiers
ISSN
1300-7777,1308-5263
E-ISSN
1308-5263
DOI
10.4274/tjh.galenos.2019.2019.0241
